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Figure S1. Synthetic scheme for the Cyclodextrin-Cy3 conjugate. 
 
 
 
Figure S2. The sequence and the fluorescence intensities corresponding to different numbers of 
Cyclodextrin-Cy3 per ssDNA strain. 
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Figure S3. Synthetic scheme for the Adamantane-BHQ2 conjugate. 
 
 
 
Figure S4. Calibration curve of compound 3 in the presence of 100 nM and 1 μM of Adamantane-BHQ2. 
This curve is fitted using a Hill function on the measured data points. Because of the competitive binding 
nature, the fluorescence intensity depends on the concentration of the Adamantane-BHQ2. 
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Figure S5. (Left) Compound 3 decreases the glutamate concentration in the cell, indicating that the 
glutamine uptake is inhibited by compound 3. The glutamate concentration was measured using the 
aforementioned kit. Because compound 3 is not a preferred substrate for glutamine transporters, it requires 
large amount of it to induce the change in glutamate concentration. In this case, the cells were incubated 
with or without 4 mM of compound 3, in the presence of 1 mM glutamine.  (Right) SLC1A5-knock down 
experiments using three different siRNA sequences. siRNA 1 was chosen for subsequent uptake 
experiments described in Fig 2. The information for involved siRNA is: siRNA 1 (ThermoFisher s12917, 
targeting NCBI NM_001145144.1, exons 2,3; location 97), siRNA 2 (ThermoFisher s12918, targeting 
NM_001145144.1, exon 5; location 371), and siRNA 3 (ThermoFisher s12917, targeting NM_001145144.1, 
exons 8; location 978). 
 
 
 
Figure S6. The result of compound 3 uptake and glutamate assays. Cells were treated with different 
concentrations of erlotinib for 24 h and then assayed. The glutamate was measured using a commercial kit 
(Abcam, ab83389). The agreement between the two measurements proves that compound 3 is a good 
surrogate for glutamine. 
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Figure S7. The toxicity test of compound 3. The cells were treated with different concentrations of 
compound 3 for 48 h, and the cell numbers were normalized to the control sample. Compound 3 not only 
did not show any inhibition towards proliferation, but rather enhanced it. The mechanism to this observation 
is unknown. However, because in the real assay, cells are only incubated with compound 3 for 30 min, 
therefore it is reasonable to assume its negligible effect. 
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Figure S8. A) Illustration of the SCBC platform and typical images of the single cell chamber and the 
corresponding fluorescence barcode result. The cell is highlighted in the red circle. B) The methods for 
quantifying i) proteins, ii) cAMP/cGMP, iii) GSH and iv) glucose uptake. The protein detection is based 
on sandwich-type immunofluorescence assay and the metabolites are measured through surface 
competition fluorescence assays. [M. Xue, et al, J. Am. Chem. Soc., 137, 4066-4069 (2015)] 
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Figure S9. The cell growth curve upon 1 μM and 10 μM of erlotinib treatment. It is obvious that 1 μM 
erlotinib cannot inhibit cell growth, while 10 μM is effectively slowing down the cell proliferation.  
 
 
 
Figure S10. Steady-state kinetic model. Under steady-state approximation,  
we have  [B] = kx [A] [Ex] and [C] = ky [A] [Ey].  
Assumption: drug perturbation doesn’t affect the rate constant k. Semiquantitative sample comparison: 
[𝐵]1
[𝐵]2
=  
𝛼𝑥1[𝐴]2
𝛼𝑥2[𝐴]1
=  
(1 − 𝛼𝑦1)[𝐴]1
(1 − 𝛼𝑦2)[𝐴]2
 
where α is the multi-sample normalized activity coefficient, ranging (0,1) 
S8 
 
 
 
Figure S11. Dendrogram of the clustering results on each SCBC data set.   
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Table S1. Capture antibodies used in this work 
Catalog# Capture Antibody Name Manufacture 
A00614 cAMP Antibody, Rabbit Polyclonal GenScript 
GTX10020 Streptavidin Antibody, Mouse Monoclonal GeneTex 
A00615 cGMP Antibody, Rabbit Polyclonal GenScript 
GTX16200 Glutathione Antibody, Mouse Monoclonal  GeneTex 
AF7687 Human/Mouse/Rat PFKM Antibody, Sheep Polyclonal R&D Systems 
AF231 Human EGFR Antibody, Goat Polyclonal R&D Systems 
AF6898 
Human/Mouse/Rat Acetyl-CoA Carboxylase Antibody,  
Sheep Polyclonal 
R&D Systems 
AF8055 Human LKB1 Antibody, Sheep Polyclonal R&D Systems 
ab110335 Anti-PDK1 Antibody, Mouse Monoclonal Abcam 
AF3696 Human c-Myc Antibody, Goat Polyclonal R&D Systems 
AF7244  Human/Mouse/Rat PKM2 Antibody, Sheep Polyclonal R&D Systems 
NBP1-55415 Lactate Dehydrogenase B Antibody, Rabbit Polyclonal Novus Biologicals 
DYC1590 Phospho-GSK-3 beta (S9) DuoSet R&D Systems 
DYC3528 Human Phospho-AMPK alpha 1 (T183) DuoSet R&D Systems 
 
 
Table S2. Detection antibodies used in this work 
Catalog# Detection Antibody Name Manufacture 
ab8326 Anti-HRP Antibody, Mouse Monoclonal Abcam 
12746 PFKP Antibody, Rabbit Monoclonal Cell Signaling 
AF7687 Human/Mouse/Rat PFKM Antibody, Sheep Polyclonal R&D Systems 
MAB3570 Human Phospho-EGFR (Y1068) Antibody, Mouse Monoclonal R&D Systems 
4407  Phospho-EGFR (Y1173) Antibody, Rabbit Monoclonal Cell Signaling 
11818 
Phospho-Acetyl-CoA Carboxylase (Ser79) Antibody, 
Rabbit Monoclonal 
Cell Signaling 
3482 Phospho-LKB1 (Ser428) Antibody, Rabbit Monoclonal Cell Signaling 
3820 PDHK1 Antibody, Rabbit Monoclonal Cell Signaling 
13871 c-Myc Rabbit mAb (Alexa Fluor 647 Conjugate) Cell Signaling 
H00003945-
M01 
Lactate Dehydrogenase B Antibody, Mouse Monoclonal Novus Biologicals 
4053 PKM2 Antibody, Rabbit Monoclonal Cell Signaling 
DYC1590 Phospho-GSK-3 beta (S9) DuoSet R&D Systems 
DYC3528 Human Phospho-AMPK alpha 1 (T183) DuoSet R&D Systems 
 
